Non-invasive cerebellar stimulation

Anew Era TMS & Psychiatry Brings TMS Therapy to Dallas, TX

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Neuroscience, Medicine, Neurotechnology, Electrotherapy, Medical devices, Neuropsychology, Treatment of depression, Transcranial magnetic stimulation, TMS, Todd M. Hutton, Non-invasive cerebellar stimulation

DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.

Key Points: 
  • DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.
  • Anew Era TMS & Psychiatry offers patients their very best chance for successful depressive symptomatic relief through the latest, most advanced, FDA cleared, non-medicinal treatment solution.
  • Breanna Splain, Managing Partner and Chief Strategic Officer at Anew Era TMS & Psychiatry, began as one of the first employees of Anew Era TMS & Psychiatry.
  • During a TMS Treatment, the electromagnetic currents stimulate nerve cells, activating regions of the brain that have become less active.

MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Electrotherapy, Neuropsychology, Medical devices, Transcranial magnetic stimulation, Non-invasive cerebellar stimulation, Transcranial stimulation

"Responsiveness to customer needs is a core part of MagVenture DNA," says MagVenture SVP of Sales, Kerry Rome.

Key Points: 
  • "Responsiveness to customer needs is a core part of MagVenture DNA," says MagVenture SVP of Sales, Kerry Rome.
  • "MagVenture is continuously striving to improve solutions to optimize the clinical practice of transcranial magnetic stimulation or TMS in short.
  • Transcranial Magnetic Stimulation is a technology that applies rapidly changing magnetic fields to stimulate specific areas in the brain.
  • MagVenture is a Danish medical device company specializing in non-invasive magnetic stimulation solutions for the clinical treatments and brain research.

BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Neurotechnology, Neuroscience, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Non-invasive cerebellar stimulation

The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/events-and-presentations/event-calendar .

Key Points: 
  • The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/events-and-presentations/event-calendar .
  • Please access the Companys website at least 10 minutes ahead of the conference call to register.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway.

Transcranial Stimulation: The "Current" Treatment for Attention-Deficit Hyperactivity Disorder

Retrieved on: 
Thursday, February 11, 2021
Branches of biology, Medicine, Clinical medicine, Neurostimulation, Electrotherapy, Neurophysiology, Neurotechnology, Transcranial direct-current stimulation, TDCS, Attention deficit hyperactivity disorder, Non-invasive cerebellar stimulation, Berenson-Allen Center for Noninvasive Brain Stimulation

However, some patients respond poorly to this treatment and suffer from adverse effects, leaving scientists on the lookout for a better alternative.

Key Points: 
  • However, some patients respond poorly to this treatment and suffer from adverse effects, leaving scientists on the lookout for a better alternative.
  • Transcranial direct current stimulation (tDCS) wherein electrical current is directly applied into the brain is known for its potential in improving cognitive function with minimal adverse side effects.
  • They found that application of tDCS significantly reduced hyperactivity, and improved memory and cognitive abilities in ADHD rats.
  • Overall, their findings open avenues for safe and effective treatment of not just ADHD, but a range of other neuropsychiatric disorders.

LIFTiD Neurostimulation Appears on "Shark Tank" and Raises Awareness of tDCS Technology's Impact

Retrieved on: 
Wednesday, November 18, 2020
Branches of biology, Neurotechnology, Medicine, Neurostimulation, Electrotherapy, Medical devices, Biology, Neurophysiology, TDCS, Transcranial direct-current stimulation, Non-invasive cerebellar stimulation, Transcranial random noise stimulation

OSSINING, N.Y., Nov. 18, 2020 /PRNewswire/ --LIFTiD Neurostimulation is a transcranial direct current stimulation (tDCS) device for consumers that uses a mild electric current to stimulate the brain.

Key Points: 
  • OSSINING, N.Y., Nov. 18, 2020 /PRNewswire/ --LIFTiD Neurostimulation is a transcranial direct current stimulation (tDCS) device for consumers that uses a mild electric current to stimulate the brain.
  • Raising national awareness of LIFTiD Neurostimulation, Ken and Allyson discussed the benefits of tDCS with investors on the show.
  • tDCS is backed by science and supported by thousands of studies, including clinical trials in a number of areas.
  • "LIFTiD uses transcranial direct current stimulation (tDCS) to depolarize neurons in specific locations in the frontal lobes," explained Dr. Theodore H. Schwartz, MD, science advisor for LIFTiD Neurostimulation.

BrainsWay Hosting Key Opinion Leader Call on Deep Transcranial Magnetic Stimulation for Treating Psychiatric Disorders

Retrieved on: 
Tuesday, November 17, 2020
Branches of biology, Neurotechnology, Neuroscience, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, Brainsway, Neurostimulation, Non-invasive cerebellar stimulation

CRESSKILL, N.J. and JERUSALEM, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced, non-invasive treatment of brain disorders, today announced that it will host a key opinion leader (KOL) call on Deep Transcranial Magnetic Stimulation (Deep TMS) for treating psychiatric disorders on Monday, November 23, 2020, at 10:00 AM Eastern Time.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced, non-invasive treatment of brain disorders, today announced that it will host a key opinion leader (KOL) call on Deep Transcranial Magnetic Stimulation (Deep TMS) for treating psychiatric disorders on Monday, November 23, 2020, at 10:00 AM Eastern Time.
  • He oversees the sites cutting-edge Deep Transcranial Magnetic Stimulation (Deep TMS) program.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

BrainsWay to Report Third Quarter 2020 Financial Results and Operational Highlights on November 18, 2020

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Neurotechnology, Neuroscience, Neurophysiology, Neuropsychology, Electrotherapy, Medical devices, Transcranial magnetic stimulation, Neurostimulation, Brainsway, Non-invasive cerebellar stimulation

The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/financial-calendar .

Key Points: 
  • The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/financial-calendar .
  • Please access the Companys website at least 10 minutes ahead of the conference call to register.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

BrainsWay to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Monday, November 2, 2020
Branches of biology, Neurotechnology, Neuroscience, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Non-invasive cerebellar stimulation, Abraham Zangen

The Company will also participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit held on November 12.

Key Points: 
  • The Company will also participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit held on November 12.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.
  • To learn more, please visit www.brainsway.com .

BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session

Retrieved on: 
Tuesday, October 6, 2020
Branches of biology, Neurotechnology, Neuroscience, Biology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Non-invasive cerebellar stimulation

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that 10 of the poster presentations accepted to the annual Clinical TMS Poster session highlight the benefits and potential of Deep TMS in the treatment of mental illnesses and brain disorders.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that 10 of the poster presentations accepted to the annual Clinical TMS Poster session highlight the benefits and potential of Deep TMS in the treatment of mental illnesses and brain disorders.
  • The Clinical TMS Society was established in 2013 and includes Transcranial Magnetic Stimulation (TMS) providers with extensive clinical and research experience from across the United States and the world.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

BrainsWay Announces Presentations at Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 2, 2020
Neuroscience, Neurotechnology, Branches of biology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Non-invasive cerebellar stimulation

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.
  • To learn more, please visit www.brainsway.com